{"name":"Arcus Biosciences, Inc.","slug":"arcus-biosciences-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":247000000,"revenueGrowth":-4.3,"grossMargin":0,"rdSpend":523000000,"netIncome":-353000000,"cash":222000000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"AB308","genericName":"AB308","slug":"ab308","indication":"Other","status":"phase_1"},{"name":"AB598","genericName":"AB598","slug":"ab598","indication":"Other","status":"phase_1"},{"name":"AB680","genericName":"AB680","slug":"ab680","indication":"Other","status":"phase_1"},{"name":"AB801","genericName":"AB801","slug":"ab801","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"IPI-549","genericName":"IPI-549","slug":"ipi-549","indication":"Solid tumors","status":"phase_2"},{"name":"SG","genericName":"SG","slug":"sg","indication":"Advanced or metastatic solid tumors (in combination with checkpoint inhibitors)","status":"marketed"}]}],"pipeline":[{"name":"AB308","genericName":"AB308","slug":"ab308","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"IPI-549","genericName":"IPI-549","slug":"ipi-549","phase":"phase_2","mechanism":"PI3K/mTOR inhibitor","indications":["Solid tumors","Non-small cell lung cancer"],"catalyst":""},{"name":"SG","genericName":"SG","slug":"sg","phase":"marketed","mechanism":"SG is an adenosine 2A receptor antagonist that blocks immunosuppressive signaling in the tumor microenvironment to enhance anti-tumor immunity.","indications":["Advanced or metastatic solid tumors (in combination with checkpoint inhibitors)"],"catalyst":""},{"name":"AB598","genericName":"AB598","slug":"ab598","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AB680","genericName":"AB680","slug":"ab680","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AB801","genericName":"AB801","slug":"ab801","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxQYk14b3NXejlUVDJkbUN0OEhMR0pCSDFDa3pzYVZCYkxHNG9mUmJLSVZ5OUZTeVVKYUpaR3FnWmxvWGlzUWZRVHFpR3NXTHNEa2N6SkcyVGlfb3hLeGp5dFkyQzI2N1dmNXp5ZzRUbWFKWWxqQmNYMUZKUWo1dml3ZUMwQjB3cXJNMzI0ZldLOTFmS0lpb0o1X0RjazMxemg5dDQwZFk1S1lKMzVMRTRCSnN6NkNDa2xIMTNmRUtHNV8tZzh1Q3AySGo1Ym1aTnJoeVh1STVnLTBxYlROSmNHQnc0LVBCUQ?oc=5","date":"2026-03-27","type":"pipeline","source":"Barchart.com","summary":"Pancreatic Cancer Treatment Pipeline Shows Strong Momentum as 170+ Pharma Companies in the Race | DelveInsight - Barchart.com","headline":"Pancreatic Cancer Treatment Pipeline Shows Strong Momentum as 170+ Pharma Companies in the Race | DelveInsight","sentiment":"neutral"},{"date":"2026-03-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQdldsellnNVdxcnV3WHhTUVNidzZBZ3dBVGlwWTZzdWs3djVvbkEyMVJaNC1ydDBKazFHdHg3cEpwS0wyVkJBajZrdVJiTkhFOFQwd0lESzV3dEZrYTdSdUVSbTZBcERMbm5NLTl4MkNYTkhiWHZPbGdvY2l4b1hIREpUbTNjeUpnWFhlUFRjbE1VQXVOMjRNa3NNTEpvYXpTVWtraG9qdzlhal9TZmsxVWFB?oc=5","date":"2026-02-27","type":"earnings","source":"TradingView","summary":"RCKT's Q4 Loss Narrower Than Estimated, Pipeline in Focus - TradingView","headline":"RCKT's Q4 Loss Narrower Than Estimated, Pipeline in Focus","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNMlVMWlBQTmZ4SzQ4TnNIQnVQQjI2QmJXblNuWnZxVndTekhGR0xWc2VaWFFoRFNhbm5MdTluTGFHcWFlUUxWMGdnS01TMmdfWW50SkNVUkcyNGZJcTZ0M2NPbkVUWWdkRjZWOXFWcy1lMnpUdUpPVDZKbkw3MVNrQllxaDg2cjRQM0N0NjFpM0d0YXMwQ1E0?oc=5","date":"2026-02-26","type":"earnings","source":"Finviz","summary":"Mirum's Q4 Earnings Lag, Higher Product Sales Drive Y/Y Revenues - Finviz","headline":"Mirum's Q4 Earnings Lag, Higher Product Sales Drive Y/Y Revenues","sentiment":"neutral"},{"date":"2026-02-25","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxONU5HanFscXh0MjZ1MnprSTRwNUxabUNfTWFHcUVPX2tJc0F4Q2trb3FDTG1lY3BLZXdzMEQ4R2NKbkJ1YXNsdkx6R3VXY0ZQcE1VTjZtWXlyTmtrZUVxLTZ1Uk9pdzBIRG1UZi16TGdYUnRObG1aWlJlc0twQTVtY3RVTTU4Y0RhQlBKSQ?oc=5","date":"2025-12-12","type":"trial","source":"BioPharma Dive","summary":"Arcus cancels work on Gilead-partnered cancer combo after trial setback - BioPharma Dive","headline":"Arcus cancels work on Gilead-partnered cancer combo after trial setback","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxQYXhzSWJ0T3hBOW5nTTZtVTAxZTRha2t5UmhEZEZ6SmNOdVlUMjVOWW1OOHpsX3hRT1RCemNEUVRacWcyamJmaXp5dVFSU2VnWllpZ0o4SURpM0dFUHdtMm5ibVhNdGtrdGJlZEtrekU5X0dKMktRVmhZQVVjaUY1T2lqdGt1Z3JOZmFkd0s2OHBEbmpJdTdsUzJndm5TYVBfSzBZTVU0SHpOLXRPRGJxMXpaSWN6NTVwMUR5TkI0eDM2alE?oc=5","date":"2025-12-12","type":"trial","source":"Reuters","summary":"Arcus scraps late-stage cancer trial after weak survival data - Reuters","headline":"Arcus scraps late-stage cancer trial after weak survival data","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-01","type":"pipeline","source":"simplywall.st","summary":"Arcus Biosciences, Inc. (NYSE:RCUS) Just Reported, And Analysts Assigned A US$29.60 Price Target - simplywall.st","headline":"Arcus Biosciences, Inc. (NYSE:RCUS) Just Reported, And Analysts Assigned A US$29.60 Price Target","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxNeVdSZ18yTV9qN05JZEl3dW9Nd092TDNSbk1NODBFcUJDV3BfQUxmTkYzaFNmai01RkYtSVJyODhJYmZIU1FBc2JhQmxkMlJ3bFZ0Q05keE9wal92aVZBU09uODFmWURKZFlfbktwSHR4blVTQV93TUg5VDk3ZXNybE1n?oc=5","date":"2025-10-07","type":"pipeline","source":"Yahoo Finance","summary":"Arcus Biosciences (RCUS) Soars 8.5%: Is Further Upside Left in the Stock? - Yahoo Finance","headline":"Arcus Biosciences (RCUS) Soars 8.5%: Is Further Upside Left in the Stock?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxORU0zMjFDLUFrN1dSYzdDRUlNR0ZRdWlhdXhwZkJPV3ZBb1U1cGptTEdvazIyUWlscmxDV0JSZV9pbndIdGExUW9rb0lBVWwwTVBFVVZrX0xNLUMwMklHWkE4TFZWVnlJNnpoX3M4Q1RVVkFXdmNXek5wUFJYdlRZUE1IMlpsQ3hwYkdmTGVTZjRnOUZ6Rkh6SS1VLXo1TDc4Um0ta1ExWS1LTExzVnc?oc=5","date":"2025-06-25","type":"pipeline","source":"BioSpace","summary":"TIGIT Turmoil: How Pharma Burned Billions on Failed Immuno-Oncology Projects - BioSpace","headline":"TIGIT Turmoil: How Pharma Burned Billions on Failed Immuno-Oncology Projects","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwJBVV95cUxPSlFhcVdwaFlONm5LenM3akJpY2hmc04zT3hMeWFVMm50ZTBMTWNZNlFWRFBUOUdJZ010blhQNkpKR1gzd2NwN0lDOXFRQlFQVmZZSW82aDRiYU94a3VaZDkxWWsxTWJGUEJlNnJWa1pGV2FEZkFLX3QyVWJJSDQ2ajgxZnVQY25wZnloZ3RBOVR4RGhSZ1REYjhHWGhzeTlmVjFmbEQ5b1ZSTktKQzltVDM0bHdBNm1DSEM2S1VSbEl0a0QybjUzZE5laFF2YTFqSkZNYlVrdXBKQm9lVjlZTTZiSDMwa3YzMUgwaHAxeV82LVNKZTFoZUI5ZG1NbThqUlE5bEFBUWJ6Rm5XcVV5Q2VWNl9NREdCN2lycUhOU2otUEh6NDBmSERtS3VPaENoMnI3M0tKRmxmTjg?oc=5","date":"2025-05-13","type":"trial","source":"GlobeNewswire","summary":"Metastatic Colorectal Cancer Clinical Trial Pipeline - GlobeNewswire","headline":"Metastatic Colorectal Cancer Clinical Trial Pipeline","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMivgJBVV95cUxOOEloNzBMUVo2VDlxYlpXM2NsZWh0Zmgyb0dZc2dWaXJNUm9adUtqNmdKaWVIWGZnbFJrdWE3bHhZeFlMYkZfc1lpb0N3TXVRQXExTUJaQUZFWFdOTlJOQjhsYkpBM2piWEhJazBwRlpKaUs2YzN0LWFyLW1OUFFSREpRM1IzbklTVkU0Y2RSUHB6TTdnNG0zUGZMVHNnWHhhVlZMRXdwNklETXVwY0tSQ2J3am82VmpRQ2dRX2d6WHh0cGg0TGR4ZEVTb1JGYXNKX2I4S0xBcDFsSWRla1JmaXEzdHdGTVlPcXVXSXJWekRLdUNzQk1VS1YzMVVQVjE2eFZLQjB6Y2JhWFZTbWZXN2l5OFRlOEYxZ3o2ZHFHMkJuMUdZM0ltX3NJRTJSNWVZTWUybThENGFlSWh4ZWc?oc=5","date":"2025-04-23","type":"pipeline","source":"PR Newswire","summary":"Metastatic Colorectal Cancer Market Poised for Expansion Across the 7MM During the Forecast Period (2025-2034) as Breakthrough Therapies Gain Traction | DelveInsight - PR Newswire","headline":"Metastatic Colorectal Cancer Market Poised for Expansion Across the 7MM During the Forecast Period (2025-2034) as Breakt","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxPOGdoZjFRRTVtbGtfQ2RaLTJjN29xYU5pWXVvdmdGcjJJazZOb1A0NVM4cEMxcmFnNnhiTnFXcGZqNl92ZWNBaGR1YVJGUzZxb0FXYmkyRHhrNnZYQ29GN3ZHTXlQc0RBX05PaXJpNDJnTmVxcEV4NFBVVE1GNnhsLS0xVDdoLTlCLUowOVphZUhaejVrZVR5djNUeU5PTHdacUE?oc=5","date":"2025-02-18","type":"pipeline","source":"Fierce Biotech","summary":"Gilead loses interest in Arcus' kidney cancer rival to Merck's Welireg - Fierce Biotech","headline":"Gilead loses interest in Arcus' kidney cancer rival to Merck's Welireg","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxNbFM1WEdMbmV1dTBXZ0dTMlVwbHJ5eENVcWtVWUp4dDBsUnFiVEo5SWhCMF81ZmtIQ205UUZKSUtGR2pnMU1zV3RFV0xzOGgyUDN2c05IV3VhUVdyYjJTNkFHV3RySUNZeGcyVU9SWjg4elpHVGNDZXN4b2hpUnAtanlBbmU3WTg0VFhtTzNmaVRiQnN4YURIelpWRWNkbnZUdTEySUVlbURlSEctYmVqQ0dnV2hlYk1CWkFVaw?oc=5","date":"2024-08-28","type":"pipeline","source":"Pharmaceutical Technology","summary":"Arcus Biosciences obtains loan facility with Hercules Capital worth $250m - Pharmaceutical Technology","headline":"Arcus Biosciences obtains loan facility with Hercules Capital worth $250m","sentiment":"neutral"}],"patents":[],"drugCount":6,"phaseCounts":{"phase_1":4,"phase_2":1,"marketed":1},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":247000000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":247000000,"period":"2025-12-31"},{"value":258000000,"period":"2024-12-31"},{"value":117000000,"period":"2023-12-31"},{"value":112000000,"period":"2022-12-31"},{"value":9487000,"period":"2020-12-31"},{"value":64530000,"period":"2020-09-30"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":523000000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-353000000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":222000000,"cashHistory":[],"totalAssets":1139000000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}